Melola Discovery

← Melola Discovery

Akses terbuka Jurnal SINTA 1

Efficacy of Quinine Sulfate in Patients with Mild-To-Moderate COVID-19: A Randomized Controlled Trial

The Indonesian Biomedical Journal · Vol. 15 No. 6 (2023) · hlm. 366–374

DOI
10.18585/inabj.v15i6.2543
ISSN
2085-3297, 2355-9179
Terbit
2023-12-11
Penerbit
Secretariat of The Indonesian Biomedical Journal
Bahasa
en
Lisensi
creativecommons.org/licenses/by-nc/4.0/

Abstrak

BACKGROUND: Before WHO revoked the emergency use authorization for Chloroquine (CQ) and Hydroxychloroquine (HCQ) because of their side effects, it was suggested to use these two drugs for COVID-19 therapy. In addition, another derivate of quinine, namely Quinine Sulfate (QS), showed good in silico and in vitro antiviral activity against SARS-CoV-2. Prior the WHO revocation, this study was conducted to evaluate the efficacy of QS in mild-to-moderate COVID-19 patients.METHODS: This was an adaptive, controlled, multicenter, randomized, double-blind clinical trial involving mild-to-moderate COVID-19 patients in Indonesia. The participants were divided into 2 groups: the control group (standard COVID-19 treatment + placebo) and the treatment group (standard COVID-19 treatment + QS). The primary outcome was the efficacy of QS based on clinical status using a 7-point ordinal scale. The secondary outcomes were the efficacy of QS in terms of the incidence and duration of oxygen supplementation, incidence of mechanical ventilation, and length of stay.RESULTS: No significant difference in the efficacy parameters studied was found between the control group and the treatment group. The difference in the mean oxygen saturation was also measured and the results showed a significant difference where the treatment group had higher mean oxygen saturation than the control group (p=0.001).CONCLUSION: Although not significant, the treatment group showed better therapy outcomes compared to the control group.KEYWORDS: clinical trials, efficacy, quinine, chloroquine, hydroxychloroquine

Kata kunci

Jaringan kolaborasi para penulis

40 penulis · 137 tautan kepenulisan bersama · 62 lintas organisasi · menampilkan 40 yang paling banyak terhubung

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Padjadjaran University
  • Hasanuddin University
  • PT Prodia StemCell Indonesia (Indonesia)
  • National Research and Innovation Agency
  • Udayana University
  • Krida Wacana Christian University
  • Kementerian Kesehatan Republik Indonesia
  • Organisasi lain
  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Andi WijayaHasanuddin University94
Nurrani Mustika DewiPadjadjaran University45
Haig Yousef BabikianAfiliasi tidak diketahui4
Iceu Dimas KulsumPadjadjaran University4
Ferdy FerdianDr. Hasan Sadikin General Hospital4
Efriadi IsmailUniversity of Indonesia4
Suryani As’ádHasanuddin University3
Irma Ruslina DefiPadjadjaran University2
Anwar SantosoUdayana University2
Ilhamjaya PatellongiHasanuddin University2
Ahmad FariedPadjadjaran University2
Cynthia Retna SartikaPT Prodia StemCell Indonesia (Indonesia)2
Rima HaifaPT Prodia StemCell Indonesia (Indonesia)2
Abdurahman RidhoPadjadjaran University2
Nuning NurcayaniAfiliasi tidak diketahui2
Zelika Mega RamadhaniaPadjadjaran University2
Rina TrianaPadjadjaran University2
Ahmad MuhtadiPadjadjaran University1
Eva FeriadiPadjadjaran University1
Charisma DilantikaAfiliasi tidak diketahui1
Luciana Budiati SutantoKrida Wacana Christian University1
Dessy PratiwiKementerian Kesehatan Republik Indonesia1
Imas MaesarohPadjadjaran University1
Muhaimin MuhaiminUniversitas Jambi1
Rizky AbdulahPadjadjaran University1
Aziiz Mardanarian RosdiantoPadjadjaran University1
Adziqa Ammara QiantoriPadjadjaran University1
Mas Rizky A. A. SyamsunarnoPadjadjaran University1
Indriyanti Rafi SukmawatiHasanuddin University1
Made Putra SemadhiPadjadjaran University1
Dewi MuliatyAfiliasi tidak diketahui1
Mansyur ArifHasanuddin University1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OpenAlex API (jurnal SINTA, ADR 0048) https://openalex.org/S2764892910, pertama di-harvest 19 Nov 2026, terakhir terlihat 19 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"><dc:title xml:lang="en">Efficacy of Quinine Sulfate in Patients with Mild-To-Moderate COVID-19: A Randomized Controlled Trial</dc:title><dc:creator>Irma Rahayu Latarissa</dc:creator><dc:creator>Melisa Intan Barliana</dc:creator><dc:creator>Anna Meiliana</dc:creator><dc:creator>Ida Paulina Sormin</dc:creator><dc:creator>Erizal Sugiono</dc:creator><dc:creator>Cissy Bana Kartasasmita</dc:creator><dc:creator>Irmansyah Irmansyah</dc:creator><dc:creator>Keri Lestari</dc:creator><dc:subject>quinine sulfate</dc:subject><dc:subject>COVID-19 pandemic</dc:subject><dc:subject>SARS-CoV-2</dc:subject><dc:subject>mild to moderate COVID-19</dc:subject><dc:subject>antiviral therapy</dc:subject><dc:subject>oxygen saturation</dc:subject><dc:subject>supplemental oxygen</dc:subject><dc:subject>mechanical ventilation</dc:subject><dc:subject>length of hospital stay</dc:subject><dc:subject>chloroquine</dc:subject><dc:subject>hydroxychloroquine</dc:subject><dc:description xml:lang="en">BACKGROUND: Before WHO revoked the emergency use authorization for Chloroquine (CQ) and Hydroxychloroquine (HCQ) because of their side effects, it was suggested to use these two drugs for COVID-19 therapy. In addition, another derivate of quinine, namely Quinine Sulfate (QS), showed good in silico and in vitro antiviral activity against SARS-CoV-2. Prior the WHO revocation, this study was conducted to evaluate the efficacy of QS in mild-to-moderate COVID-19 patients.METHODS: This was an adaptive, controlled, multicenter, randomized, double-blind clinical trial involving mild-to-moderate COVID-19 patients in Indonesia. The participants were divided into 2 groups: the control group (standard COVID-19 treatment + placebo) and the treatment group (standard COVID-19 treatment + QS). The primary outcome was the efficacy of QS based on clinical status using a 7-point ordinal scale. The secondary outcomes were the efficacy of QS in terms of the incidence and duration of oxygen supplementation, incidence of mechanical ventilation, and length of stay.RESULTS: No significant difference in the efficacy parameters studied was found between the control group and the treatment group. The difference in the mean oxygen saturation was also measured and the results showed a significant difference where the treatment group had higher mean oxygen saturation than the control group (p=0.001).CONCLUSION: Although not significant, the treatment group showed better therapy outcomes compared to the control group.KEYWORDS: clinical trials, efficacy, quinine, chloroquine, hydroxychloroquine</dc:description><dc:publisher>Secretariat of The Indonesian Biomedical Journal</dc:publisher><dc:date>2023-12-11</dc:date><dc:type>info:eu-repo/semantics/article</dc:type><dc:format>application/pdf</dc:format><dc:identifier>https://doi.org/10.18585/inabj.v15i6.2543</dc:identifier><dc:identifier>10.18585/inabj.v15i6.2543</dc:identifier><dc:source>The Indonesian Biomedical Journal; Vol 15 No 6 (2023); 366-374</dc:source><dc:source>2085-3297</dc:source><dc:source>2355-9179</dc:source><dc:language>en</dc:language><dc:relation>https://inabj.org/index.php/ibj/article/download/2543/674</dc:relation><dc:rights>https://creativecommons.org/licenses/by-nc/4.0/</dc:rights></oai_dc:dc>